Biktarvy Patent Protection
9 patents · Gilead Sciences Inc.
Patent Details
| Patent # | Title | Assignee | Expires | Status |
|---|---|---|---|---|
| 9296769 | Drug substance & product patent (incl. pediatric exclusivity extension) | Gilead Sciences Inc. | Feb 15, 2033 | 6.6y left |
| 8754065 | Drug substance & product patent (incl. pediatric exclusivity extension) | Gilead Sciences Inc. | Feb 15, 2033 | 6.6y left |
| 9216996 | Drug substance & product patent | Gilead Sciences Inc. | Dec 19, 2033 | 7.5y left |
| 9732092 | Drug substance & product patent | Gilead Sciences Inc. | Dec 19, 2033 | 7.5y left |
| 10385067 | Orange Book listed patent | Gilead Sciences Inc. | Jun 19, 2035 | 9.0y left |
| 9708342 | Drug substance & product patent | Gilead Sciences Inc. | Jun 19, 2035 | 9.0y left |
| 12594244 | Drug product (formulation / method-of-use) patent | Gilead Sciences Inc. | Nov 8, 2036 | 10.4y left |
| 11744802 | Drug product (formulation / method-of-use) patent | Gilead Sciences Inc. | Nov 8, 2036 | 10.4y left |
| 10548846 | Drug product (formulation / method-of-use) patent | Gilead Sciences Inc. | Nov 8, 2036 | 10.4y left |
Related Drug Patent Expirations
5 patents · earliest expires 2032 · AstraZeneca AB
1 patents · earliest expires 2034 · Bayer Intellectual Property GmbH
45 patents · earliest expires 2031 · AbbVie Inc.
1 patents · earliest expires 2031 · Eli Lilly and Company
8 patents · earliest expires 2036 · Eli Lilly and Company
3 patents · earliest expires 2030 · Celgene Corporation
The Biktarvy record above pulls directly from the FDA Orange Book and USPTO patent records. What follows is the per-entity context — how Biktarvy sits in the broader U.S. pharmaceutical patent expirations distribution and which underlying factors drive the headline numbers.
Every number on this page links back to the FDA Orange Book and USPTO patent records; the methodology page describes the inputs, refresh cadence, and known limitations of the underlying data product.
For readers using this page as a decision input, the related-entity pages elsewhere on the site provide the comparison set. The most useful comparison for Biktarvy is typically a peer within U.S. brand-name drugs with similar size, similar exposure, or similar geography — not the national-level summary alone.